Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Shattuck Labs, Inc.NASDAQ: STTK

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $10.95M rose 10.4% year over year, ahead of the -40.4% change in trailing-twelve-month research & development. Sequentially, it rose 20.9% from the prior quarter. Over 3 fiscal years it compounded at -24.8% a year.

Context

  • Research & development amounted to 3527.3% of revenue in FY2025, up 2352.5 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10.4% holds above the trailing-twelve-month pace of -40.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.95M+20.9% QoQ
Last fiscal yearDec 2025
$35.27M-47.5% YoY
LTMMar 2026
$36.3M-40.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.4%——
1 year-47.5%——
3-year CAGR-24.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
35.27M USD
Year-over-year change
-47.5%
4-year CAGR
-11.1%

Research & Development vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -40.4% is the 9th highest of 10, against a peer median of -17.1%.
  • Research & development amounts to 3629.9% of revenue for STTK, versus a peer median of 63.8%.
STTK Competitors
Research & Development for STTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$241.88M USD-19.7%+0.6%63.8%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$145.36M USD+345.0%+69.4%1223.2%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$68M USD+23.2%+5.9%29.9%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
FTHFaeth Therapeutics, Inc.LTM Jun 2026$31.84M USD+107.0%-28.2%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$30.06M USD-37.6%-19.5%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M USD+47.2%-19.1%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$16.65M USD-23.2%-13.5%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥13.28M CNY-94.8%-61.3%—
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$7.02M USD-17.1%+13.9%—
Peer median (excluding STTK) —-17.1%-13.5%63.8%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.